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Molecular-based allergy (MA) diagnostics is an approach used to map the allergen sensitization of a patient at a
molecular level, using purified natural or recombinant allergenic molecules (allergen components) instead of
allergen extracts. Since its introduction, MA diagnostics has increasingly entered routine care, with currently more
than 130 allergenic molecules commercially available for in vitro specific IgE (sIgE) testing.
MA diagnostics allows for an increased accuracy in allergy diagnosis and prognosis and plays an important role in
three key aspects of allergy diagnosis: (1) resolving genuine versus cross-reactive sensitization in poly-sensitized
patients, thereby improving the understanding of triggering allergens; (2) assessing, in selected cases, the risk of
severe, systemic versus mild, local reactions in food allergy, thereby reducing unnecessary anxiety for the patient
and the need for food challenge testing; and (3) identifying patients and triggering allergens for specific
immunotherapy (SIT).
Singleplex and multiplex measurement platforms are available for MA diagnostics. The Immuno-Solid phase
Allergen Chip (ISAC) is the most comprehensive platform currently available, which involves a biochip technology
to measure sIgE antibodies against more than one hundred allergenic molecules in a single assay. As the field of
MA diagnostics advances, future work needs to focus on large-scale, population-based studies involving practical
applications, elucidation and expansion of additional allergenic molecules, and support for appropriate test
interpretation. With the rapidly expanding evidence-base for MA diagnosis, there is a need for allergists to keep
abreast of the latest information. The aim of this consensus document is to provide a practical guide for the
indications, determination, and interpretation of MA diagnostics for clinicians trained in allergology.* Correspondence: canonica@unige.it
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 In summary, molecular allergy (MA) diagnostics is
increasingly entering routine care, and currently,
more than 130 allergenic molecules are commercially
available for in vitro specific immunoglobulin E
(sIgE) testing.
 MA diagnostics may initially appear complicated;
however, with increasing experience, the information
gained is generally simple and provides relevant
information for the allergist. This is especially true
with regard to food allergy and for the selection of
specific immunotherapy.
 Nevertheless, all sIgE tests including MA diagnostics
should be evaluated within the framework of a
patient’s clinical history, since allergen sensitization
does not necessarily imply clinical responsiveness.
 Clinicians and immunologists specifically trained in
allergology must keep abreast of the new and rapidly
evolving evidence available for MA diagnostics.
In the late 1960s, the discovery of the immunoglobulin
(IgE) antibody provided a specific biomarker that could
be used to identify allergic diseases triggered by environ-
mental allergens (i.e., generally proteins). Traditional IgE
antibody tests such as skin prick tests (SPT) or in vitro
specific IgE (sIgE) tests are based on crude extracts
composed of allergenic and non-allergenic molecules
obtained from an allergenic source. With the application
of DNA technology in the late 1980’s, allergenic mole-
cules were characterized and cloned in order to resolve
the determinants of various allergic diseases [1-4]. The
availability of allergenic molecules in the last decade
has ushered in a new phase of diagnostics, termed
molecular-based allergy (MA) diagnostics, that allows
for improved management of allergic diseases [5].
Today, many of the most common allergenic molecules
have been cloned or purified, have had their three-
dimensional structures elucidated, and can be consistently
produced [6]. Because of the growing number of allergens
identified, a systematic allergen nomenclature, approved
by the World Health Organization and International
Union of Immunological Species (WHO/IUIS) Allergen
Nomenclature Subcommittee, has been established. The
subcommittee is in charge of developing and maintaining
the systematic nomenclature developed for allergenic mol-
ecules, as well as a comprehensive database of known al-
lergenic proteins that can be accessed at www.allergen.org.
Allergenic molecules are named using their Latin family
name (genus and species). For example, allergens that
begin with Phl p are from Phleum pratense (timothy
grass). A number is added to the name to distinguish the
various allergens from the same species (e.g., Phl p 1, Phl
p 2, etc.). The numbers are assigned to the allergens in theorder of their identification. Allergenic molecules are clas-
sified into protein families, according to their structure
and biological function [7]. Many different molecules
share common epitopes (antibody binding sites) and the
same IgE antibody can bind and induce an immune re-
sponse to allergenic molecules with similar structures
from various allergen sources. These cross-reactive aller-
gens give valuable information regarding sensitization to
several different sources. In contrast, some molecules are
unique markers for specific allergen sources, allowing for
the identification of the primary sensitizer.
MA diagnostics is increasingly entering routine care
and can improve management of allergic patients. This
is particularly evident in food allergy [8-10]. Knowledge
of the allergenic molecules the patient is sensitized to
can help to discriminate between likelihood of local
versus systemic reactions and persistence of clinical
symptoms. For example, some allergens such as storage
proteins in peanuts (e.g. Ara h 2) and nuts (e.g. Cor a 9)
have been shown to be associated with severe reactions,
while other allergens cause sensitization mostly without
a clinical reaction. Another important aspect, difficult to
elucidate using traditional tests, is the stability of the
allergen. Allergens that are stable to heat and digestion
(e.g., Ara h 2 from peanut) are more likely to cause se-
vere clinical reactions, whereas heat and digestion labile
molecules (e.g., Ara h 8 from peanut) are more likely to
cause milder, local reactions or be tolerated. Similarly,
identifying whether the sensitization is genuine in nature
or due to cross-reactivity help to evaluate the likelihood
of reaction on exposure to different allergen sources [8].
Molecular diagnostics may also improve the selection of
both patients and specific allergens for specific immuno-
therapy (SIT) for inhalant allergies (e.g., for pollen)
[11,12] and hymenoptera venom allergy [13,14]. An ever
increasing number of studies focusing on different aller-
genic molecules or allergic diseases are rapidly being
published. However, the search for more, clinically rele-
vant molecules is needed and ongoing.
The presence of IgE antibodies against allergenic mol-
ecules may be determined using a singleplex (one assay
per sample) or multiplex (multiple assays per sample)
measurement platform. A singleplex platform allows the
doctor to select those allergenic molecules necessary for
an accurate diagnosis defined by the clinical history of
the patient. The multiplex approach allows for charac-
terization of the IgE response against a broad array of
pre-selected allergens on a chip independently of the clin-
ical history. There is one commercially available multiplex
immuno-solid phase allergen chip (ISAC) which contains
more than 100 allergens from about 50 allergen sources.
The large number of allergens provides extensive and de-
tailed information about a patient’s sensitization profile
[12,15]. ISAC is especially suited for use in patients with
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technology is a promising MA approach for improved
diagnosis, prognosis, and selection of patients for SIT.
While it is a commercial product, it has been the mainstay
of many investigator studies so far.
In summary, with increasing experience, MA diagnostics
is generally straightforward to interpret and can provide
relevant, additional information for the allergist. However,
the clinical utility of many of the allergenic molecules
needs further investigation. Because of the speed at which
new data on MA diagnostics is becoming available, clini-
cians are required to keep pace with a large amount of
novel information. This WAO - ARIA - GA2LEN consen-
sus document on Molecular-based allergy diagnostics pro-
vides a practical guide for the indication, determination,
and interpretation of MA diagnostics that is aimed for cli-
nicians specifically trained in allergology.Definitions and concepts
Allergen source
A tissue, particle, food or organism inducing allergy (e.g.
cat dander, D. pteronyssinus, milk, Aspergillus fumigatus,
Phleum pratense pollen, etc.).Allergen extract
A crude, unfractionated mixture of allergenic and non-
allergenic proteins, polysaccharides, and lipids obtained by
extraction from an allergen source (e.g., pollen grains).Allergenic molecule (allergen component)
A molecule (i.e., protein or glycoprotein) derived from a
given allergen source that is identified by sIgE antibodies
(hereafter referred to as allergen). Allergens can be iso-
lated from natural allergen sources (native, purified aller-
gen) or can be produced by using recombinant DNA
technology (recombinant allergen).Stability of allergens
Allergens that are susceptible to acid pH in context with
peptic digestion (relevant at the gastric level) are not
able to cross the gastric barrier (except possibly in pa-
tients treated with antacid drugs [16]). Temperature
(cooking or boiling) susceptibility indicates that the al-
lergen does not maintain its allergenicity after cooking/
heating procedures. Heating may occur in the industrial
processing of food for production and in domestic
cooking. The structure of allergens susceptible to prote-
ase digestion is affected by gastric and pancreatic en-
zymes. Accordingly, allergens sensitive to these factors
are considered labile, while those that are not are con-
sidered to be stable.More about allergenic molecules
A genuine allergen causes specific sensitization to its
corresponding allergen source. Major allergens are de-
fined as those that bind to IgE in 50% or more of pa-
tients with the same allergy; in other words, the majority
of patients (≥50%) with the same allergy are sensitized to
the allergen in question. A primary allergen is the ori-
ginal sensitizing molecule (i.e., the driving trigger; in
contrast to secondary sensitization due to cross-reac-
tivity). In general, major allergens are also genuine and
primary. Finally, the abundance of a molecule present
in the allergen source is also a parameter to take into
consideration.
Cross-reactivity: the phenomenon of an IgE antibody
recognizing, binding, and inducing an immune response
to similar allergenic molecules (homologues) present in
different species; for example, an IgE antibody that binds
and reacts to both Bet v 1 in birch pollen and Cor a 1 in
hazelnut due to their structural similarity (generally char-
acterized by greater than 50%-70% sequence homology be-
tween the primary structures of the proteins). IgE cross-
reactivity often occurs between the following:
a) Allergenic molecules in closely related species (e.g.,
between grass or between mite allergens);
b) Well preserved molecules with similar function
present in widely different species that belong to the
same protein family (e.g., members of the
tropomyosin protein family, such as Der p 10 in
house dust mite and Pen m 1 in black tiger shrimp).
Component resolved diagnostics (CRD)
See molecular-based allergy diagnostics.
Co-sensitization
Genuine sensitization to more than one allergen source
(e.g., timothy grass and birch), where the sensitization is
not due to cross-reactivity.
CCD
Cross-reactive carbohydrate determinant. CCDs are
carbohydrate moieties of glycoproteins. The most com-
monly described is MUXF3 [17].
Epitope
The region of the protein recognized and bound by an
antibody (i.e., the antibody binding site).
Molecular-based allergy (MA) diagnostics
A diagnostic approach to define the allergen sensiti-
zation of a patient at the molecular level using purified
natural or recombinant allergen on singleplex or multi-
plex measurement platforms.
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A cross-reactive allergen, belonging to a protein family
well preserved throughout many widely different species,
able to trigger IgE antibody binding (e.g., profilins or
serum albumins). See also definition of cross-reactivity (b).
Recombinant allergen
An allergenic molecule produced using DNA cloning
and protein purification techniques. Recombinant aller-
gens can be produced with consistency in terms of qual-
ity and amounts, and without CCD structures. Allergen
extracts cannot be produced by recombinant techniques.
sIgE concentration/level
a) High level: represents a high concentration of sIgE
antibodies specific for an allergenic extract or
molecule. Generally, the higher the sIgE level the
higher the probability of clinical reactions. Some
allergens also have a high probability of inducing
severe reactions at low sIgE concentrations (e.g.,
storage proteins and lipid transfer proteins [LTPs]),
while others typically do not result in any clinical
reactions despite high sIgE concentrations (e.g.,
cross-reactive carbohydrate determinants [CCD]).
b) Low level: Represents a low concentration of sIgE
antibodies specific for an allergen extract or molecule.
sIgE sensitization
Presence of allergen-specific IgE (sIgE) antibodies in the
blood that may occur in the presence or absence of clin-
ical symptoms.
a) Mono-sensitization: Sensitization to one allergen
source (Dermatophagoides pteronyssinus) or to a
closely related taxonomical family or group of
allergen sources (i.e., mites).
b) Poly- (or multi-) sensitization: Sensitization to three
or more allergen sources (e.g., mite, birch, and grass
pollen).
sIgE detection based on allergen extracts
Singleplex or multiplex platforms for in vitro measure-
ment of sIgE reactivity to allergen extracts. Terms such as
CAP, radioallergosorbent test (RAST), sIgE and in vitro-
test are often used interchangeably for this technique.
However, the performance of different measurement plat-
forms differs and this should be taken into consideration
when reporting and comparing results. This approach
cannot identify cross-reacting molecules.
sIgE detection based on allergenic molecules
Singleplex or multiplex platforms for in vitro measure-
ment of sIgE reactivity to allergenic molecules.Increase accuracy and resolve cross-reactivity
 One of the most important implications of
molecular-based allergy (MA) diagnosis is its ability
to distinguish genuine sensitization from sensitization
due to cross-reactivity.
 This information helps the clinician to determine
whether a single, a few closely related, or several widely
different allergen sources need to be considered.
Allergic individuals may produce IgE antibodies to al-
lergens that are either unique to a single species or com-
mon to many. Thus, the individual may show a genuine
sensitivity to a given allergen or may show sensitivity to
many unrelated species as a consequence of immuno-
logical cross-reactivity to structurally related allergens.
In general, the closer the taxonomical relationship be-
tween species, the higher the degree of structural and
immunological similarity between the allergens.
However, proteins with important biological functions
are often well preserved and ubiquitous throughout re-
lated and unrelated species. Proteins are classified into
protein families according to their biological function
and structure [7]. Proteins within the same family share
common epitopes and the same IgE antibody can bind
to similar structures present in allergens from differ-
ent allergen sources. These cross-reactive allergens give
valuable information on potential sensitization and clin-
ical reactions to several different sources. For example,
IgE antibodies formed against either pathogenesis-related
(PR)-10 protein family members Bet v 1, a birch pollen
allergen, or Mal d 1, an apple allergen, cross-react and
give rise to sensitivity to both birch and apple. Examples
of other common cross-reacting allergen families are
listed in Additional file 1: Table S1 [8,18-25]. It is worth
noting that some cross-reacting molecules can cause
clinically relevant symptoms, while others usually do not.
While, MA studies have not fully elucidated the under-
lying mechanism governing cross-reactivity and symp-
tom presentation, it is likely that analysis of the epitopes
of key allergens will provide insight into this issue [26].
Currently, a large number of purified or recombinant
allergens are commercially available. Additional file 2:
Table S2 provides an overview of available allergens
for in vitro testing, as of January 2013.
In contrast, specific allergens are markers for their re-
spective allergen sources, allowing identification of the
primary sensitizer. One of the most important clinical
uses of MA is its ability to identify the offending aller-
genic molecule and to distinguish specific molecules
from markers of cross-reactivity. Thus, the probability
of a clinical reaction on exposure to different allergen
sources may be defined, in some cases, by the pattern of
sensitization to different allergens.
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demonstrated its ability to play an important role by
increasing the accuracy of diagnosis. As an example of
this, in peanut allergic patients, sensitization to Ara h 2
is considered a genuine marker for peanut that may
induce systemic reactions, while Ara h 8 is a marker for
cross-reactivity among food allergens and Fagales tree
pollen and is mainly associated with mild, oral reactions
[8,27]. Therefore, measuring IgE responses to certain
food allergens may reduce the need for food challenges
[28-30]. In patients sensitized to different pollen species,
MA diagnostics is able to improve the resolution of a
conventional diagnostics obtained by skin tests in a sub-
stantial number of cases, either by detecting new rele-
vant sensitizations or by ruling out clinically irrelevant
sensitizations caused by non-symptomatic cross-reactive
allergens [11,31]. For example, MA diagnostics can help
to distinguish baker’s asthma from pollen or wheat
allergy [32].
In conventional SPTs, some allergens can be poorly
represented in extracts because of the biological varia-
bility of the allergen source. For instance, Can f 5, a
prostate-derived allergen produced by male dogs, is a
dog allergen responsible for sensitivity in up to 38% of
dog-allergic patients [33]. Allergen extracts used in skin
tests, however, typically use dog hair as an allergen
source. As a result, these skin tests routinely fail to iden-
tify patients’ sensitivity to Can f 5, likely due to its low
concentration in dog hair [33]. Determination of the IgE
response to Can f 5 using MA diagnostics may enhance
the accuracy of dog allergy diagnosis.
When testing a limited panel of molecules, only what
is measured can be detected; in other words, when using
Phleum pratense positive SPT or sIgE test, Phl p 1 and
Phl p5 will be able to define genuine sensitization, while
Phl p 7 and Phl p 12 will identify sIgE for polcalcins and
profilins, respectively. The presence of other molecules
such as Phl p 2 and Phl p 4 could improve the accuracy
of the diagnosis. If all of these molecules are studied, a
fairly representative IgE profile for P. pratense would be
obtained; if only one or a few molecules are evaluated,
the characterization of the IgE profile would be less
accurate. Thus, the descriptive quality of the sIgE profile
will be based on the choice of tests prescribed by the
clinician.
Nevertheless, it must be kept in mind that all allergy
diagnostics, including MA, should be evaluated within the
framework of a patient’s clinical history, because IgE
sensitization towards a given allergen does not necessarily
imply clinical responsiveness. This is of particular import-
ance, since allergic patients respond in an individualized
manner to exposure to allergens from various sources, i.e.,
every individual produces their own unique IgE antibody
profile at the molecular level [12].Assess the risk and type of reaction
 Molecular-based allergy (MA) diagnostics have
emerged into routine care due to its ability to
improve risk assessment, particularly for
food allergies.
 Different foods contain unique allergenic molecules
that are stable or labile to heat and digestion. The
stability of a molecule and a patient’s clinical history
help the clinician evaluate the risk of systemic versus
local reactions. Labile allergens are linked to local
reactions (typically oral symptoms) and cooked food
is often tolerated, whereas stable allergens tend to be
associated with systemic reactions in addition to
local reactions.
 MA diagnostics may decrease the need for
provocation testing and improve recommendations
for allergen avoidance.
Risk assessment of allergic individuals is one potential
application of MA diagnostics. Since patient sensitization
profiles may differ with regard to disease expression and
severity, detecting “low-risk” versus “high-risk” molecules
is an area of major interest that could reduce the use of
potentially harmful diagnostic procedures such as chal-
lenge tests. Such knowledge may also improve allergy
management recommendations to patients (e.g., exposure
reduction). This has been shown with the use of MA diag-
nostics in food, venom, respiratory and latex allergy [8,34].
In addition, the sensitization profile of a patient may
impact overall symptomatology, as poly-sensitization to
several different allergens from a single allergen source
may increase symptom severity [27,35].
Nevertheless, it must be noted that information may
only be applicable to the specific population which has
been studied, since it is known that both food and inhal-
ant sensitization profiles and disease expression differ
according to local exposures patterns characteristic of
the geographical region [36].
Food allergens
Generally, allergens resistant to heat and digestion often
trigger more severe allergic reactions (i.e., anaphylaxis)
compared to labile allergens, the latter which typically in-
duce local symptoms such as oral allergy syndrome (OAS)
(Table 1). In addition, the amount of a molecule present in
a food source is also a parameter to take into consider-
ation. The following text provides a few examples of how
IgE sensitization to different allergens from a food allergen
source can result in clinically unique reactions.
Peanut
Allergen sensitization profiles in peanut-allergic individ-
uals have been extensively studied. IgE antibodies against
Table 1 High- versus low-risk molecules from foods
giving rise to anaphylaxis
Source High risk Low risk
Peanut Ara h 1, 2, 3, 9 Ara h 8, profilin, CCD
Hazelnut Cor a 8, 9, 14 Profilin, CCD
Walnut Jug r 1, 2, 3 Profilin, CCD
Soy Gly m 5, 6, (4) Profilin, CCD
Rosacea fruits Pru p 3, Mal d 3 Pru p 1, Mal d 1, profilin, CCD
Wheat Tri a 14, Tri a 19 Profilin, CCD
KEY: CCD = Cross-reactive Carbohydrate Determinant.
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sociated with genuine peanut reactions; in contrast, iso-
lated sensitization to Ara h 8 (PR-10 protein and Bet v
1- homologue) is a marker of milder or local symptoms
[24,27,35,37]. In southern Europe, the LTP (Ara h 9) is a
prevalent sensitizing allergen that may act as a marker
of severity, as it is associated with systemic and more se-
vere reactions [8]. Further studies in other geographical
regions are needed for Ara h 9 [36]. Finally, patients
with profilin or CCD sensitization to peanut alone usu-
ally react with no or local oral symptoms, and heated
peanuts may be tolerated.
Soy
Sensitization to Gly m 5 and/or Gly m 6 has been asso-
ciated with severe reactions in allergic patients, while
Gly m 4 (PR-10) is commonly associated with OAS [38].
Nevertheless, in birch pollen-allergic individuals, the
combination of Gly m 4 sensitivity and intake of large
amounts of midly processed soy, such as soy drinks, can
induce a severe reaction [39]. Patients with profilin or
CCD sensitization to soy alone usually exhibit no, or local
oral symptoms, and heated soy may be tolerated.
Hazelnut
While sensitization to Cor a 1 (PR-10) is associated with
local reactions like OAS, Cor a 8 (LTP) and storage pro-
teins (e.g. Cor a 9 and Cor a 14) are more frequently rec-
ognized by IgE antibodies from patients with severe
symptoms [40-42]. Patients with profilin (Cor a 2) or CCD
sensitization to hazelnut alone usually exhibit no or local
oral symptoms and heated hazelnuts may be tolerated.
Walnut
Severe reactions in walnut-allergic patients are associated
with storage protein (Jug r 1, Jug r 2) or LTP (Jug r 3)
sensitization [43]. Walnut allergens have not been avail-
able on the market until recently, as is reflected by the lack
of recent clinical studies. Patients with profilin or CCD
sensitization to walnut alone usually exhibit no, or local
oral, symptoms and heated walnut may be tolerated.Wheat
Sensitization to ω-5-gliadin (Tri a 19) is a risk factor for
immediate allergic reactions in children and for systemic
exercise-induced reactions in adults [44-46]. The wheat
LTP (Tri a 14) shows some degree of cross-reactivity
with other food LTPs, however more knowledge is
needed about its prevalence and clinical implication. Pa-
tients with profilin or CCD sensitization to wheat alone
usually exhibit no, or local oral, symptoms and heated
wheat may be tolerated.
Rosaceae fruits
Apple, peach, and other stone fruits are members of the
Rosaceae family. In patients allergic to these fruits, par-
ticularly to allergens such as PR-10 proteins (Mal d 1,
Pru p 1) or profilins (Pru p 4), local, oral reactions are
more frequent, since these protein families are sensitive
to heat and digestion. In contrast, sensitization to LTP
(Pru p 3), typical of the Mediterranean area, is associated
with a wide range of clinical expressions (from asymp-
tomatic to anaphylaxis), and is generally considered a
risk marker for severe reactions including co-factor
(e.g., exercise, alcohol or drugs) dependent anaphylaxis
[25,47-50].
Egg
High levels of sIgE antibodies to ovomucoid (Gal d 1) have
been identified as a risk factor for persistent egg allergy,
including reactions to cooked/heated egg, while undetect-
able levels indicate tolerance to cooked egg [51].
Milk
Casein (Bos d 8) and beta-lactoglobulin (Bos d 5) sIgE
antibodies are markers of persistent allergy to milk, includ-
ing heated milk, in milk allergic patients while undetect-
able levels indicate tolerance to baked milk products [52].
Fish
Parvalbumins (e.g., Gad c1 and Cyp c 1) are the major al-
lergens in fish and are typically stable to heat and diges-
tion. Parvalbumins show a high degree of cross-reactivity
whereby patients sensitized to one parvalbumin may also
react to parvalbumins from other fish, including carp,
cod, herring, plaice, mackerel, tuna, salmon, perch,
and eel [53-55].
Shellfish
Allergic reactions to crustaceans may be caused by tropo-
myosin, which shows high degree of cross-reactivity across
a wide variety of species, including mites [56]. Shrimp and
other shellfish also contain other clinically relevant aller-
gens, like sarcoplasmic calcium-binding protein and argin-
ine kinases [57].
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Galactose-α-1,3-galactose (α-Gal) is a sugar structure
found on glycoproteins and glycolipids of non-primate
mammals and new world monkeys, but not on humans.
IgE-antibodies specific for α-Gal (anti-α-Gal-IgE) may
be associated with severe allergic symptoms and with
delayed-type anaphylaxis [58,59]. α-Gal is also present
on cat IgA which does not show high allergenic activity
[60], and on gelatine containing material. It is assumed
that sensitization to α-Gal can be induced by tick
bites or certain parasite infections [61-63]. Clinically,
α-Gal–sensitized patients may experience delayed imme-
diate type reactions to red meat (beef, pork, goat, deer)
anaphylaxis [58,59].
α-Gal is also present on the chimeric antibody
cetuximab (cancer drug), and patients sensitized to
α-Gal may react with anaphylactic reaction after the
administration of cetuximab. Testing for α-Gal before
administration of cetuximab should therefore be con-
sidered [64].
Bovine serum albumin (e.g. Bos d 6) is a heat labile
allergen present both in milk and beef, which may cause
cross-reactivity between different mammalian meat [65].Inhalants
Pet dander
Higher levels of sIgE antibodies against Fel d 1 are associ-
ated with asthma in cat-allergic individuals [66]. Recogni-
tion of more than three animal-derived allergens such as
lipocalins (Mus m 1, Equ c 1, Fel d 4, Can f 1, 2), kallikrein
(Can f 5), and secretoglobin (Fel d 1) has been associated
with severe asthma in Swedish children [67]. More know-
ledge is needed in the area of pet allergy where many of
the patients are poly-sensitized to several pets and the
clinical history is often inconclusive, in addition the cross-
reactivities between e.g. cat, dog and horse is not fully
clarified at the MA level.Pollen
Research in pollen allergy has focused on distinguishing
genuine allergens from those that are cross-reactive,
however, little is known regarding specific markers of se-
vere reactions. Nevertheless, some sensitivities to spe-
cific allergens may be markers of more severe symptoms
in pollen allergy, increasing the risk of systemic reactions
during immunotherapy, such as Ole e 9 and the pollen
LTP Ole e 7 [68].
Profilin sensitization is common among pollen allergic
patients and it is usually associated with mild or no
clinical symptoms. However, for a minority of patients,
profilin may be a risk factor for more severe reactions in
olive pollen-allergic individuals and in patients allergic
to certain plant foods like melon or citrus [8,25].Mites
Although no specific sensitization profile has been
described as a risk factor for lower airway disease or
disease severity, a higher sIgE/IgG4 ratio for Der p 2 has
been associated with asthma [69,70]. Der p 10 (tropomy-
osin) is a minor allergen in mite-allergic patients,
however it may still indicate a risk for allergic reactions
to shellfish or snail, which can be severe [71].
Molds
In hypersensitivity reactions to Aspergillus fumigatus,
the presence of IgE antibody reactivity to Asp f 2, 4, and
6 may suggest allergic bronchopulmonary aspergillosis
(ABPA) [72], whereas sensitization to Asp f 1 and/or
Asp f 3 may be more indicative of allergic asthma [73].
These associations must still be confirmed in other
patient populations.
Cockroach
It was recently described that sensitization to Per a 2
correlates with severity of airway allergy in cockroach-
allergic patients [74]. Per a 2 is currently not commer-
cially available for in vitro testing; however, the Per a 2
homologue Bla g 2 is available. Cockroaches also contain
cross-reactive tropomyosin (Bla g 7), which indicates a




Sensitization to Hev b 8 (profilin) seems to be clinically
irrelevant and not related to clinical latex reactions. The
other latex allergens are linked to clinical reactions;
however, no association between allergens and severity
of reactions has been identified so far [75,76]. The cross-
reactive allergen responsible for the so called latex-fruit
syndrome are not fully clarified, although data indicate
that Hev b 5, 6 and 11 play a role [8,77].
Hymenoptera venoms
Most hymenoptera venom allergens possess CCDs that
are responsible for a portion of clinically irrelevant IgE
antibody cross-reactivity between bee and wasp venom.
Detection of recombinant venom allergens can discrim-
inate between genuine venom sensitization and cross-
reactivity due to CCDs in patients with double-positive
IgE results from traditional venom tests that are based
on allergen extract [8,13,14].
Specific immunotherapy
 Molecular-based allergy (MA) diagnostics represents
a useful tool to distinguish genuine sensitisations
from cross-reactions in poly-sensitized patients, when
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unable to identify the relevant allergen(s) for specific
immunotherapy (SIT).
 Given that SIT is an expensive treatment typically
used over longer periods of time (3 to 5 years), correct
diagnosis, selection of truly eligible patients, and
identification of primary sensitizing allergen(s) are
important for optimal and cost-effective patient
management.
Specific immunotherapy (SIT) involves the administra-
tion, either subcutaneously or sublingually, of an extract
of the allergen responsible for clinical symptoms to in-
duce tolerance and reduce reactivity (i.e., symptoms) to
the allergen itself [78,79]. This is achieved through com-
plex immune modifications that involve both humoral
and cell-mediated immunity [80]. As a paradigm, aller-
gen immunotherapy is “specific”, meaning that it only
modifies the immune response against the allergen for
which the vaccination is being performed. As a conse-
quence, a precise etiological diagnosis is required for the
prescription of SIT, whereby the allergen responsible for
clinical symptoms must be unequivocally identified. In
some patients, a detailed clinical history and traditional
extract-based IgE testing (SPT and/or in vitro sIgE) is
sufficient to identify the relevant allergen(s) [81]. This is
especially true in the case of allergy to plants with a well-
defined pollen season, which does not overlap significantly
with that of other plants or other allergen sources.
However, the complexity of diagnosis increases when
the patient demonstrates poly-sensitization by traditional
diagnostic tests based on allergen extracts and their clin-
ical history is not sufficient to clarify the nature of the
sensitization. This may occur in a relatively high propor-
tion of patients [82,83]. In the United States, for in-
stance, such cases would involve preparing a vaccine for
SIT by mixing together all of the allergens that a patient
tests positive for [84,85]. Mixing numerous allergens ap-
pears to achieve good clinical efficacy; however, there
may be an inability to identify the responsible allergen in
the case of adverse events [86].
It is well recognized that, in many cases, multiple
positive results obtained with allergen extracts (i.e., SPT
and/or in vitro sIgE) are due to the presence of cross-
reactive allergens in the diagnostic extracts [87,88].
Certain proteins (e.g., profilins, polcalcins, LTPs, PR10,
tropomyosins) are highly conserved in a wide variety of
species. For instance, a patient who is primarily sensi-
tized to grasses may also test positive for birch with SPT
[89]. This cross-reactivity occurs because the birch ex-
tract used in SPT contains profilin (e.g., Bet v 2), which
are largely similar to those in grasses (e.g., Phl p 12).
Indeed, the use of recombinant/purified allergens
would allow for the discrimination between genuinesensitizations and cross-reactivities. In the example
mentioned above a patient with sIgE antibodies against
Phl p 1 and Phl p 5 but no sIgE to Bet v 1 is truly sensi-
tized to grass. If sIgE antibodies to Phl p 12 (profilin)
were also detected, profilin sensitization would probably
be responsible for the positive SPT result obtained with
birch extract, which contains profilin as well. Thus,
using knowledge gained through the identification of
allergens, SIT would be prescribed for grass only. Simi-
larly, if a patient is sensitized to a traditional house dust
mite extract, but their IgE antibodies are specifically
directed against Der p 10 (tropomyosin) and not to Der
p 1, 2/ Der f 1, 2, SIT for mites should not be given, be-
cause mite extracts mainly contain Der p 1, 2/Der f 1, 2
and have variable or low amounts of Der p 10. Molecu-
lar diagnostics can also improve the selection of patients
for hymenoptera venom SIT. Sensitization to the major
allergens Api m 1 of honeybee and Ves v 5 and/or Ves v
1 of yellow jackets may be helpful in discriminating
between true double bee and wasp sensitization and
cross-reactivity due to CCDs [13].
In addition, most commercial allergen extracts used in
SIT are well standardized for major allergens, but con-
tain only minimal or variable amounts of minor aller-
gens [90,91]. Thus, patients with sensitization to minor
allergens alone will likely not receive sufficient amounts
of allergen to achieve a successful outcome by SIT. A
recent study reported that patients receiving a 2-year
course of SIT with either birch or grass pollen had a
much more favourable outcome with SIT when sen-
sitization to the marker allergens of birch or grass pollen
were detected compared to patients sensitized to only
minor, cross-reactive allergens [92].
In poly-sensitized patients, the most relevant sensitiz-
ing allergens for which SIT should be prescribed can be
more clearly identified with MA diagnostics. A recent
study reported that the use of MA diagnostics modified
the prescription of SIT compared to SPT in more than
50% of patients [11], suggesting that poly-sensitized
patients are at risk of incorrect SIT prescription.
Theoretically, a detailed identification of molecules to
which IgE antibodies are directed against would allow
for tailored SIT based only on allergens with a docu-
mented IgE response for each patient. In practice, this
does not seem feasible. First, the number of possible
combination of sensitization profiles is large when
taking into consideration all allergenic sources, [12];
second, recombinant vaccines do not perform better
than traditional allergen extracts, as observed in some
studies [93,94]; and third, each single recombinant/
purified allergen would need to be individually tested
and registered, which carries a substantial financial
burden for manufacturers. Thus, the reality of patient-
tailored SIT is still a distant prospect [95].
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 Molecular multiplex platforms help the clinician to
obtain an overview of the sensitization profile of the
patient with a small amount of serum and to
identify cross-reacting, unanticipated, or potentially
high risk allergens.
 Currently one multiplex platform is available on
the market (the Immuno-Solid phase Allergen Chip
(ISAC) platform). While not interchangeable, ISAC
results are similar with those obtained from
singleplex platforms. However, at low sIgE levels
ImmunoCAP is more sensitive than ISAC and this
should be considered when interpreting ISAC
results with regard to patient clinical history.
 Poly-sensitized pediatric and adult patients in whom
sensitization to cross-reacting allergens is suspected
are most suited for ISAC testing, especially when
both food and airborne allergens are involved.
MA diagnostics has been available on singleplex plat-
forms such as the ImmunoCAP, ImmuLite, and HyTech
platforms for many years. These platforms use panels of
single allergens together with the corresponding allergen
extract. Presently, MA diagnostics can also be performed
using multiplex technology to measure sIgE antibodies
against multiple allergens in a single assay [96]. This
technique allows for the testing of a large number of al-
lergens using a small amount of serum. Several research
platforms have been described in the literature, whereof
one, ImmunoCAP Immuno-Solid Phase Allergen Chip
(ISAC) (Phadia AB) is commercially available. The first
European Conformity (CE)-certified version of ISAC was
developed and launched by VBC-Genomics, Vienna, in
2003. The initial chip contained 23 allergens, and, since
then, it has continually been improved by providing a
larger number of allergens. In 2007, the chip contained
103 allergens and in 2011 the ISAC 112 chip was made
commercially available.
ImmunoCAP ISAC is a miniaturized immunoassay
platform, where allergens are immobilized in a micro-
array. A minimum of 30 μl of serum or plasma, obtained
from either capillary or venous blood, is needed to probe
the chip. The assay consists of a polymer-coated glass
slide that contains four microarrays, suitable for assaying
four simultaneous samples. The allergens are spotted in
triplicate and covalently immobilized on the chip. The
procedure consists of the following two main steps:
(1) IgE antibodies from a patient’s sample bind to the
immobilized allergens and (2) allergen-bound IgE anti-
bodies are detected by a fluorescence-labeled anti-IgE
antibody. The test procedure, including all washing and
incubation steps, can be performed in a total assay time
of less than four hours. Fluorescence is measured with alaser scanner and results are evaluated using a Micro-
array Image Analysis (MIA) software, which provides an
automatic readout of the results. In addition, add-
on software is available (ISAC Xplain) that delivers
evidence-based allergen information relevant for the in-
dividual patient. Using a standard calibration curve,
results are reported within a range of 0.3 to 100 ISAC
Standardized Units (ISU-E), giving a semi-quantitative in-
dication of IgE antibody levels. This differs from the units
used to report ImmunoCAP results (kU/L), and as such,
these measurements are not interchangeable, although
they correlate well [97]. Furthermore, it must be born in
mind that the ImmunoCAP technology measures IgE
binding under conditions of excess of immobilized aller-
gen whereas ISAC uses low amounts of immobilized
allergen allowing for competition with allergen-specific
isotypes other than IgE.
Several studies, summarized in Table 2, have analyzed
the reproducibility of this immunoassay and have com-
pared the ISAC chip with other methods of measuring
sIgE [31,97-102]. Overall, the results of the ISAC assay are
reproducible at a level that is generally accepted and
agreed upon. However, special attention is recommended
when samples contain low levels of sIgE (0.3–1 ISU-E), as
a higher degree of variability in low-level results has been
observed. When comparing ISAC with other sIgE measur-
ing assays such as the singleplex ImmunoCAP platform,
concordance of results vary between allergens tested
[31,76,97-99,102,103]. Comparative data with the Immu-
Lite or HyTech platforms are not available in the litera-
ture. Nevertheless, newer versions of ISAC have resolved
a number of observed discrepancies. Because there is a
higher degree of between assay variability for ISAC com-
pared to ImmunoCAP, ISAC is generally not recom-
mended for monitoring quantitative IgE levels over time
in clinical routine. While no interference from very high
total IgE has been observed [98], a potential for interfer-
ence between IgE and other isotypes, principally IgG, has
been indicated (e.g., during SIT) [104].
The use of allergen microarrays has not only improved
allergy diagnosis [15,98] and optimized management of
SIT [11], some studies also indicate that microarrays can
be used to analyse the allergic march [105], sensitization
in preclinical stages and molecular spreading [106,107].
Although sensitivity compared to ImmunoCAP is still
often lower, ISAC can have high clinical relevance by
detecting sensitization patterns to important allergens
and cross-reacting groups. In addition, the broad aller-
gen panel offers the potential for identifying unantici-
pated triggers. In a recent study that followed patients
for over 30 years, sensitization detected specifically to
Aln g 1 led to the identification of a newly planted and
imported alder tree (A. spaethii) as the most probable
source responsible for a number of cases of unexplained
Table 2 Studies comparing different techniques for specific IgE determinations
Techniques compared Allergens Main findings References
ImmunoCAP & ISAC 50 HDM, cat dander, birch, grass, and
mugwort pollen
ROC curves demonstrated that CAP and ISAC performed equally well in cat, birch,
and grass pollen. ISAC was slightly less sensitive in HDM and displayed a reduced
sensitivity in mugwort pollen.
Wöhrl et al. [99]
ImmunoCAP &
ISAC prototype
Betula and grass allergens Comparable sensitivity between CAP and ISAC. Jahn-Schmid et al. [100]
ImmunoCAP & ISAC 103 grass and cypress pollen Showed similar diagnostic performance. Cabrera-Freitag et al. [101]
ImmunoCAP & ISAC 103 Multiples allergens Concordance was 78.65% for positive results.Concordance was 93.57%
for negative results.
Gadisseur et al. JACI [98]
Reproducibility of ISAC 103
rApi g 1, rBet v 2, nBos d 4, nGal d 1,
nGal d 2, nGal d 3, rHev b 8, rPhl p 5,
rPhl p 6, and rPhl p 7
Excellent intra-slide, intra-assay, and inter-assay variability. rApi g 1, nGal d 3,
and rPhl p 6 showed high variability in the individual analyses.
Cabrera-Freitag et al. [101]
ImmunoCAP & ISAC 103 Latex allergens Similar performance Ebo et al. [76]
ImmunoCAP, ISAC 103, &
ADVIA-CENTAUR
Pollen allergens The 3 diagnostic methods were in agreement in 62.5% of cases. ISAC showed a deficiency
in the detection of sensitivities to Salsola and Plantago; Advia-Centaur did not detect
sensitizations to cypress. The concentration of sIgE in ISAC and ADVIA were significantly
correlated for most pollen allergens.
Lizaso et al. [31]
ImmunoCAP & ISAC 103 103 ISAC molecules For low ISU values (0.3 to 1), the within-assay CV was very high (>100%), as expected;
for medium (1 to <15) and high (15 or higher) ISU values, the CV was 17% and 8%
respectively. The corresponding between-assay CVs were >100%, 33%, and 13.2%, respectively.
Melioli et al. [97]
ImmunoCAP & ISAC 103 Alt a 1 Similar performance Twaroch et al. [103]
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than expected. This was supported by the fact that these
hybrid alder trees flowered earlier than allergen sources
native to the area [108].
Table 3 summarizes the advantages and limitations of
different IgE measurement techniques. When deciding
if and when to use the microarray technology, it is
helpful to consider the number of allergens to be
tested; in general (depending on the local price and
reimbursement system), if more than 10 to 12 allergens
are required for an accurate diagnosis using single-
plex tests, then a microarray test may be preferable
both for the information obtained and for economic
reasons [15].
The interpretation of the results of a 112-allergen
assay may be challenging, even for the experienced and
trained ISAC user. First, the clinical relevance of the
different allergens must be considered. Second, the re-
sults must be evaluated in relation to traditional diag-
nostic tests. Finally, and most importantly, the results
must be evaluated with regard to the patient’s clinical
history. Indeed, while the vast majority of molecules
cover the spectrum of positive traditional tests, it is
known that ISAC results for some allergen sources such
as cashew nut, sesame, dog, mugwort, and ragweed can
be nega-tive, even when the extract-based test is posi-
tive. This is obviously the case if the triggering allergenTable 3 Advantages and disadvantages of ISAC, immunoCAP,
Advantages
ISAC • 30 μl of serum or plasma (capillary or venous blood)
• 112 allergens can be assayed in parallel
• Natural and recombinants proteins
• Less allergen needed (approximately 100, 000-fold, pg vs. μ
per assay
• No interference from very high total IgE
ImmunoCAP • Automatic method
• Quantitative assay
• High sensitivity
• Lower coefficient of variation
• Natural or recombinants proteins or crude extracts
• Appropriate for monitoring sensitization
Skin prick test • High sensitivity (extract-dependent)
• Immediate readingis not present on the chip. The standard strategy used to
evaluate an ISAC result is outlined in Figure 1.
In summary, while not interchangeable, the results
generated with the ISAC chip are similar to those
obtained with the ImmunoCAP platform. One disad-
vantage to the technique is that the sensitivity of ISAC is
lower than that of ImmunoCAP, particularly when sIgE
levels are low. However, the ability to use a small
amount of serum to obtain a patient’s sensitization pro-
file, identify cross-reacting allergens, and detect unsus-
pected or potentially harmful allergens are advantages of
the use of ISAC in allergy diagnosis in patients with
allergy-like symptoms (e.g. asthma, rhinitis, eczema,
urticaria idiopathic anaphylaxis or eosinophilic esopha-
gitis (EoE)).
Patients most likely to benefit from molecular-
based allergy diagnostics
 Molecular-based allergy (MA) diagnosis is most
useful for selection of SIT, evaluation of cross-
reactivity, and assessment of severity of reaction
associated with various allergens.
 Patients who are poly-sensitized, have an unclear
symptom and/or sensitization pattern, or who do not
respond to their treatment may be routinely





g) • More variability in the inter-assay analysis for certain allergens
• Greater coefficient of variation
• Some allergen sources are not included
• Less appropriate for monitoring sensitization
• Potential interference between IgE and other isotypes,
principally IgG
• 40 μl of serum per allergen
• One allergen per assay
• Detect low-affinity antibody that may have little to no clinical relevance
• Manual
• One allergen per prick
• Only crude extracts
• Not appropriate for monitoring sensitization
Figure 1 ISAC Interpretation flow chart.
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history and symptom profile may not benefit
from MA diagnostics compared to traditional
diagnostic tests.
MA diagnostics offers several advantages useful for the
examination of allergic patients with symptoms like e.g.,
asthma, rhinitis, eczema, urticaria, gastrointestinal, oral al-
lergy syndrome or anaphylaxis. Identification of genuine
sensitization is as important as the identification of sec-
ondary sensitizations caused by cross-reacting allergens.
MA diagnostics, based on either the physician’s choice of
single allergens or the use of a microarray, offers a large
amount of information pertaining to the IgE profile of sen-
sitized patients. This information is mainly useful for three
purposes. First, MA diagnostics is helpful in the identifica-
tion of a genuine sensitization to an allergen source, par-
ticularly when SIT is being considered. MA diagnostics is
often essential to the accuracy of prescribed SIT for a large
proportion of allergic patients [8]. Second, MA diagnostics
can detect sensitization to certain cross-reacting protein
families of allergens, thereby contributing to identify the
triggering allergen source and to improve the recommen-
dations made to patients regarding exposure avoidance. Fi-
nally, MA diagnostics helps to assess the risk associated
with certain allergens (i.e., type of reaction, local or sys-
temic). For example, sensitization to LTP or storage pro-
teins may cause severe, systemic reactions in allergic
patients while profilin, CCD and PR-10 proteins generally
are associated with mild, local reactions in food allergy.From among those potentially eligible for MA diag-
nostics, different patient categories can be defined. In
most patients, MA diagnostics may be considered a use-
ful and interesting, but not essential, tool, particularly
when only symptomatic treatment is prescribed. Mono-
sensitized patients (e.g., to pet or mite allergens) and pa-
tients with a clear case history and symptom profile do
not generally seem to derive benefit from MA diagnos-
tics compared to traditional diagnostic tests.
Previously, patients who were sensitized to one or two
allergen sources were the most prevalent patient type in
clinical practice; currently, they are becoming a minority,
mainly in developed countries. In fact, poly-sensitized
pediatric and adult patients with complex symptoms, as
well as patients in whom sensitization to cross-reacting
allergens is suspected, should be carefully considered for
MA evaluation. Within this population, patients with
documented poly-sensitization to one or more inhalants,
but also suffering from food allergy (i.e., from less severe
manifestations such as OAS to more severe, including
anaphylaxis, asthma or eczema) should be routinely con-
sidered for evaluation using MA diagnostics. In addition,
MA diagnostics may offer additional information for early
diagnosis of allergies and may aid in the monitoring of the
evolution of the allergic disease, useful for preventive indi-
cations to the patient.
In conclusion, current guidelines of allergy diagnosis
should recommend a thorough clinical investigation as
a first-line approach, followed by allergen extract test-
ing using in vitro sIgE or SPT tests as a second-line
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experienced users MA may be included in second-
line testing.
Unmet needs
 Molecular-based allergy (MA) diagnostics enhances
the clinical utility of specific IgE (sIgE) antibody-
based allergy diagnostics nevertheless; a number of
unmet needs have yet to be addressed.
Molecular analysis of allergen sensitization patterns
can enhance the clinical utility of allergy tests based on
extracts. In selected cases it may also reduce the need
for challenge testing for food allergies and may also
improve the selection of SIT prescription. However,
there are a number of unmet needs pertaining to MA
diagnostics:
1) Large-scale, population-based multicenter studies
are needed to further define in which categories of
patients MA diagnostics may be beneficial.
2) The practical use and selection of allergens in MA
diagnostics need to be evaluated in large studies that
include well-characterized patients and healthy,
sensitized controls representative of different
geographical regions.
3) Evaluation of the incremental benefits relative to the
incremental costs for MA diagnostics, by way of
cost-utility studies, is needed. These studies should
compare the effectiveness of MA diagnostics with
the traditional in vitro sIgE or SPT techniques that
are currently available.
4) Identification and clinical evaluation of the most
relevant allergens have to be further investigated in
many allergen sources.(e.g., nuts, molds, tree and
weed pollen).
5) Training efforts in both the clinical and research
settings is warranted, with a focus on developing
this new “molecular” era in allergology.
6) Development of clinical decision support is needed
to prevent misinterpretation and improve knowledge
as the amount of information obtained from MA
diagnostics may be complex, especially as the
evidence for MA is rapidly progressing.
There are additional needs in the field of allergy
diagnostics including traditional tests based on extracts.
Currently there is one published cost effectiveness ana-
lysis on food allergy diagnostics [109]. In this guideline
document, economic evidence shows that both IgE anti-
body testing and skin prick testing are cost effective
compared to clinical anamneses without testing. Since
MA diagnostics increase the accuracy in selected foodallergies (e.g. peanut allergy) and selection of SIT pre-
scription compared to traditional tests based on extracts,
the cost effectiveness should logically increase for these
particular scenarios. However, the fact that only one cost
effectiveness analysis in food allergy is available under-
lines the need for more cost effectiveness analysis in
allergy diagnostics.
There is also a need for characterization and stan-
dardization of allergen concentrations in allergen ex-
tracts that are used in diagnostic testing and treatment.
Summary and conclusions
 International guidelines recommend a thorough
clinical case history as a first-line approach and
allergen extract-based IgE tests (in vitro specific IgE
or skin prick test) as a second-line investigation.
 Molecular-based allergy (MA) diagnostics is
considered a third-line approach to be used for
patients in whom first- and second-line investigations
were inconclusive. For experienced users MA may be
included in second-line testing.
 MA diagnosis is a new and complex procedure that,
in the near future, will represent a standard tool in
the allergist’s armamentarium. Educational
programs on MA diagnostics for allergists
are needed.
MA diagnostics was developed more than a decade
ago. The recent availability of a greater number of aller-
gens has substantially modified the diagnostic approach
used by many allergists. Currently, international guide-
lines recommend a thorough clinical case history as a
first-line approach and allergen extract-based IgE tests
(in vitro specific IgE or skin prick test) as a second-line
investigation for the identification of the allergen source
responsible for a patient’s symptoms. SPT and in vitro
sIgE tests provide similar information and the associ-
ated advantages and disadvantages of both types of tests
are dependent on the clinical case. For the majority of
patients, first- and second-line investigation is sufficient
to define the nature of a patient’s allergy. Molecular-
based allergy (MA) diagnostics is considered a third-
line approach to be used for select patients in whom
first- and second-line investigations were inconclusive.
For experienced users MA may be included in second-
line testing.
Traditional diagnostic tests have been considered suffi-
cient for the identification of the best SIT prescription
in the majority of patients. With the identification of
specific and cross-reacting allergens, a number of new
diagnostic and therapeutic options are available to aller-
gists, including the ability to choose the allergen com-
position for SIT.
Canonica et al. World Allergy Organization Journal 2013, 6:17 Page 14 of 17
http://www.waojournal.org/content/6/1/17MA diagnostics is relatively expensive compared with
traditional tests, especially with regard to the microarray
technology. Economic consideration or budget limita-
tions may influence the decision in the individual pa-
tient, whether using a singleplex or multiplex approach.
The number of allergens to be tested may influence this
decision, both for economical reason, amount of infor-
mation gained and for the overall serum volume re-
quired (especially in young children).
When making the choice to use the microarray diag-
nostics, it is important to consider the primary advan-
tage which is that with a small serum or blood sample, a
broad spectrum analysis of a patient’s IgE profile can be
performed. However, a disadvantage is that patients may
be at risk of revealing unanticipated sensitivities, possibly
to potentially harmful molecules. Although this could
also be considered as an advantage, the interpretation of
such sensitization in clinically unresponsive patients is
difficult or even impossible.
Although MA diagnostics is a complex area, it pro-
vides novel and relevant information for the allergist and
will soon become a standard tool in the allergist’s arma-
mentarium. Educational programs training allergists on
the use and interpretation of MA are highly needed.
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